BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Device Startup, Adagio Medical Gets $2.5 Million Investment but Stays Quiet on Technology for Heart Disease


4/5/2013 8:55:39 AM

New medical device company Adagio Medical might be laying low, but its executives revealed in a securities filing this week that the California startup has secured a $2.5 million investment. There’s not much publicly available information about what the Laguna Hills-based company is working on, aside from the fact that it’s “focused on finding innovative ways to treat cardiovascular disease in order to improve the quality of people’s lives,” according to its LinkedIn page. Founded in 2011, it’s a portfolio company of Fjord Ventures, a technology accelerator that provides venture capital and hands-on support to medical startups. Olav Bergheim and Hugh Neuharth, the managing director and chief financial officer at Fjord Ventures, respectively, are listed in the filing as company executives. Bergheim has held management positions at Baxter Healthcare, Immunotherapy Worldwide, BioTech Europe, Baxter Germany and Domain Associates. Neuharth is also the chief financial officer for Cianna Medical, which is developing a method of treatment for early stage breast cancer.

Read at News Release

 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES